Adamax

Adamax is a synthetic nootropic peptide engineered by combining two existing research compounds: the Semax heptapeptide backbone (Met-Glu-His-Phe-Pro-Gly-Pro, derived from ACTH(4-10)) and the adamantane modification strategy first demonstrated in P-21 (a CNTF-derived nootropic peptide). It carries N-terminal acetylation and a C-terminal adamantane-glycine-amide extension, distinguishing it from both standard Semax and N-Acetyl Semax Amidate.

Adamax has existed as a research compound for only a few years and has no independent published research. All mechanistic claims are extrapolated from its parent compounds. It is sold exclusively through research peptide vendors and carries no regulatory approval in any jurisdiction.

The Semax backbone contributes the established mechanisms of the parent compound: upregulation of BDNF and NGF in the hippocampus, modulation of the melanocortin system (MC4/MC5 receptors), and influence on dopaminergic and serotonergic neurotransmission. N-terminal acetylation blocks aminopeptidase degradation, extending plasma half-life relative to unmodified Semax.

The adamantane modification at the C-terminus is the defining structural innovation. Adamantane is a rigid, lipophilic cage molecule that dramatically increases membrane permeability and blood-brain barrier (BBB) penetration. In P-21, the same modification was shown to convert a peripherally inactive CNTF-derived sequence into an orally bioavailable, BBB-penetrant compound with robust neuroplasticity effects in mice. Applied to the Semax backbone, the adamantane moiety is theorized to produce greater CNS bioavailability and extended duration of effect compared to standard Semax or N-Acetyl Semax Amidate, potentially allowing effective activity at lower doses.